| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00775-009-0615-4 |
| P698 | PubMed publication ID | 20091072 |
| P50 | author | Julia Kaźmierczak-Barańska | Q96637078 |
| Stefan Wirth | Q82514071 | ||
| Barbara Nawrot | Q88931472 | ||
| P2093 | author name string | Marcin Cieslak | |
| Ingo-Peter Lorenz | |||
| Christoph J Rohbogner | |||
| Stefan Donevski | |||
| P2860 | cites work | Theoretical analysis on the transition state of the anticancer drug trans-[PtCl2(isopropylamine)2] and its cis isomer binding to DNA purine bases | Q94845854 |
| Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade | Q24311006 | ||
| A short history of SHELX | Q25938995 | ||
| INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE | Q28202030 | ||
| Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria | Q29616614 | ||
| Molecular mechanisms involved in cisplatin cytotoxicity. | Q34058522 | ||
| Unusual DNA binding modes for metal anticancer complexes | Q34071185 | ||
| Synthetic metallomolecules as agents for the control of DNA structure. | Q34576464 | ||
| Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. | Q34588747 | ||
| Rhodium and its compounds as potential agents in cancer treatment | Q34671630 | ||
| Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes | Q36271774 | ||
| Metal-based antitumour drugs in the post genomic era. | Q36446191 | ||
| New trends for metal complexes with anticancer activity | Q37044080 | ||
| Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. | Q37246984 | ||
| KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients | Q37313183 | ||
| Metal complexes, their cellular targets and potential for cancer therapy | Q37411425 | ||
| Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity. | Q40144221 | ||
| Ovarian cancer activity of cyclic amine and thiaether metal complexes | Q40162240 | ||
| A series of unconjugated ferrocenyl phenols: prospects as anticancer agents | Q40246541 | ||
| Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions | Q40322945 | ||
| Biological evaluation of novel Pt(II) and Pd(II) complexes with pyrazole-containing ligands | Q40508485 | ||
| Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design. | Q42576712 | ||
| Water-soluble polycationic dendrimers with a phosphoramidothioate backbone: preliminary studies of cytotoxicity and oligonucleotide/plasmid delivery in human cell culture | Q44786480 | ||
| Effect of ring methylation on the photophysical, photochemical and photobiological properties of cis-dichlorobis(1,10-phenanthroline)rhodium(III)Chloride | Q46474133 | ||
| Ruthenium Anticancer Compounds: Challenges and Expectations | Q57507152 | ||
| Determination of cobalt in feedingstuffs by solvent extraction and graphite furnace atomic-absorption spectrophotometry | Q70698488 | ||
| Inhibition of transcription in vitro by anticancer active dirhodium(II) complexes | Q73004549 | ||
| Current status of platinum-based antitumor drugs | Q77367180 | ||
| Non-platinum chemotherapeutic metallopharmaceuticals | Q77367185 | ||
| P433 | issue | 3 | |
| P921 | main subject | iridium | Q877 |
| rhodium | Q1087 | ||
| P304 | page(s) | 429-440 | |
| P577 | publication date | 2009-12-19 | |
| P1433 | published in | Journal of Biological Inorganic Chemistry | Q3186899 |
| P1476 | title | Rhodium(III) and iridium(III) complexes with 1,2-naphthoquinone-1-oximate as a bidentate ligand: synthesis, structure, and biological activity | |
| P478 | volume | 15 |
| Q43655859 | A relativistic DFT methodology for calculating the structures and NMR chemical shifts of octahedral platinum and iridium complexes. |
| Q39029785 | Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands. |
| Q39391809 | Cellular impact and selectivity of half-sandwich organorhodium(III) anticancer complexes and their organoiridium(III) and trichloridorhodium(III) counterparts |
| Q42400560 | Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands |
| Q28834484 | Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands |
| Q40506281 | Identification and characterization of antibacterial compound(s) of cockroaches (Periplaneta americana). |
| Q59010351 | Kinetic and Mechanistic Studies on the Interaction of Glycyl-L-alanine, Glycyl-L-asparagine, and Glycyl-L-tyrosine with Hydroxopentaaquarhodium(III) Ion |
| Q39032170 | Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand. |
| Q38199383 | Metallomics insights into the programmed cell death induced by metal-based anticancer compounds. |
| Q34415646 | Novel C,N-chelate rhodium(III) and iridium(III) antitumor complexes incorporating a lipophilic steroidal conjugate and their interaction with DNA. |
| Q36942237 | Novel enantiopure cyclopentadienyl Ti(IV) oximato compounds as potential anticancer agents. |
| Q37715044 | Organoiridium complexes: anticancer agents and catalysts |
| Q34331245 | Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C(∧)N-Chelated and Pyridine Ligands |
| Q39097585 | Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes |
Search more.